Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
March 16, 2019
Regenerative Medicine Earnings Scorecard - Q4/18 - to date
February 26, 2019
Sage Therapeutics (SAGE) prices 3.33 M share offering at $150.00
January 21, 2019
RegMed Investors’ (RMi): worried about 2019, investors better be!
January 15, 2019
Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50
November 23, 2018
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
November 7, 2018
Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT
November 6, 2018
Quarterly (Q3) results special: IONS, ONCE, QURE and VCEL
September 11, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
August 17, 2018
Gene editing stocks, time to harvest some upside?
8 hours 36 min ago
RegMed Investors’ (RMi) pre-open: gain or pain
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors